Delivery Order VA25913D0313-VA25914J5474

The National Institutes of Health National Institute on Drug Abuse awarded a $288,375 firm fixed price purchase order to Curia Global Inc., doing business as Amri, to provide non-GMP synthesis of up to 100 ligands that bind the KIAA0203 protein. Under the terms of the contract, Amri will synthesize the ligands in 2-10 milligram quantities over a one-year period of performance. Amri must dedicate two full-time scientists and one part-time scientist at 25% effort to update progress. There is no...

This is a federal contract award from the National Institute on Drug Abuse (NIDA), a civilian agency, to Altasciences Clinical Kansas Inc., a for-profit contract research organization (CRO). The $1,340,461.88 firm fixed-price delivery order is for a clinical trial to assess the safety, tolerability, and pharmacokinetics of an investigational agent for substance use disorder (SUD) treatment. The contract is part of NIDA's $21 million indefinite delivery contract N01DA-23-8935, which supports...

Altasciences Clinical Kansas Inc., a contract research organization based in Overland Park, Kansas, received a delivery order valued at $1.84M from the National Institute on Drug Abuse (NIDA) to conduct pharmacokinetic and pharmacodynamic trials supporting medication development for substance use disorders. Specifically, the delivery order, designated N01DA-23-8935, focuses on Phase 1 cocaine drug interaction studies scheduled to run from September 25, 2023, through October 22, 2025. The work...

The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $2.1 million firm fixed price purchase order to Avista Pharma Solutions, Inc., doing business as Cambrex, for the acquisition of two kilograms of cGMP-grade GS-441524 drug substance with an option for two additional kilograms. The drug substance will support preclinical and Phase I clinical studies by the NIH to evaluate GS-441524's potential as a COVID-19 treatment through assessing its safety,...

The National Institute on Drug Abuse awarded a $3.3 million cost-plus-fixed-fee definitive contract to Research Triangle Institute (RTI International) on August 4, 2019, for analytical chemistry and stability testing of treatment drugs for substance use disorders. The five-year contract, designated N01DA-19-8950, runs through August 3, 2024, and is performed at RTI's Research Triangle Park, North Carolina facility. No set-aside designation was applied to this award. RTI International, a...

This is a $3,562,513 cost-plus-fixed-fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc. The contract is for pharmacokinetic and pharmacodynamic studies to support the development of medications for substance use disorders. The contract period of performance is from September 20, 2017 to September 19, 2022, with an ultimate completion date of July 31, 2025. This award is not associated...

This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $113,400 contract is part of the NIH Bioanalysis Testing Services 2015-2020 IDIQ (Indefinite Delivery/Indefinite Quantity) vehicle. The work involves conducting pharmacokinetic assessments, toxicity studies, and ion channel testing services to support drug discovery and development efforts, including evaluating...

The Research Triangle Institute - doing business as RTI International - has been awarded a $1,297,307 cost plus fixed fee delivery order contract by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to provide preparation and distribution of research drug products from March 20, 2022 through March 19, 2023. The prime contractor RTI International will utilize its facilities in Research Triangle Park, North Carolina to fulfill the task order...

This federal contract award to PPD Development LP, a global contract research organization (CRO), provides regulatory consulting assistance for a medical device developer under the Blueprint MedTech program. The $370,621 cost-plus-fixed-fee contract includes research and development for clinical studies, pre-submission assessment, and package preparation. The award is issued by the National Institute on Drug Abuse, a civilian agency, and is not set aside. PPD Development LP is a subsidiary of...

The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a firm fixed-price purchase order valued at $22,500 to the University of Kansas Center for Research, Inc. This award is pursuant to a request for quote to develop a manufacturable tablet formulation of the compound NCGC72 for use in dog sarcoma clinical studies. The prime contractor will non-GMP manufacture 1,500 tablets total, with 1,000 tablets at 50mg dosage and 500 tablets at...